Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 9
30
Diseases
486
Unique genes
0.273
Avg. similarity score
Therapy related acute myeloid leukemia and myelodysplastic syndrome
Most-connected disease (20 links)
Disease
Searched: Mast cell neoplasm
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
Mast cell neoplasm
Therapy related acute myeloid leukemia and myelodysplastic syndrome
Neutrophilic leukemia
Acute myeloid leukemia, t(3;5)(q25;q34)
Myelodysplastic/myeloproliferative neoplasm
Acute leukemia of ambiguous lineage
Blast phase chronic myelogenous leukemia, bcr-abl1 positive
Therapy-related myeloid neoplasm
Cd4+/cd56+ hematodermic neoplasm
Chronic eosinophilic leukemia, not otherwise specified
Systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease
Myeloid neoplasm
Myeloproliferative disease, unclassifiable
Essential thrombocythemia
Myelofibrosis
Myeloproliferative disorder
Promyelocytic leukemia
B-lymphoblastic leukemia/lymphoma
Polycythemia vera
Myelogenous leukemia
Thrombocytosis
Lymphoid neoplasm
Myelomonocytic leukemia
Systemic mastocytosis
T-lymphoblastic lymphoma
Testicular leydig cell tumor
Central nervous system anaplastic large cell lymphoma
Early-onset combined immunodeficiency with low ig due to dominant-negative ikaros mutation
Clonal hematopoiesis
Immunodeficiency, common variable, 14
Member diseases (most connected first ‐ the cluster's core)
Top shared genes (genes linked to 2+ member diseases ‐ top 100 shown, download for all)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| ASXL1 | 23 / 30 | Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm and 19 more |
| JAK2 | 23 / 30 | Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm and 19 more |
| TET2 | 23 / 30 | Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm and 19 more |
| DNMT3A | 22 / 30 | Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Cd4+/cd56+ hematodermic neoplasm, Central nervous system anaplastic large cell lymphoma and 18 more |
| IDH2 | 20 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm, Central nervous system anaplastic large cell lymphoma and 16 more |
| TP53 | 20 / 30 | Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), B-lymphoblastic leukemia/lymphoma, Blast phase chronic myelogenous leukemia, bcr-abl1 positive and 16 more |
| EZH2 | 19 / 30 | Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Cd4+/cd56+ hematodermic neoplasm, Chronic eosinophilic leukemia, not otherwise specified and 15 more |
| KIT | 19 / 30 | Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm and 15 more |
| LOC100506403 | 19 / 30 | Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm and 15 more |
| NRAS | 19 / 30 | Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm and 15 more |
| FLT3 | 18 / 30 | Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), B-lymphoblastic leukemia/lymphoma, Blast phase chronic myelogenous leukemia, bcr-abl1 positive and 14 more |
| NPM1 | 17 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm, Central nervous system anaplastic large cell lymphoma and 13 more |
| SRSF2 | 17 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), Cd4+/cd56+ hematodermic neoplasm, Chronic eosinophilic leukemia, not otherwise specified, Essential thrombocythemia and 13 more |
| U2AF1 | 17 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm, Chronic eosinophilic leukemia, not otherwise specified and 13 more |
| CBL | 16 / 30 | Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Chronic eosinophilic leukemia, not otherwise specified and 12 more |
| ETV6 | 16 / 30 | Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), B-lymphoblastic leukemia/lymphoma, Blast phase chronic myelogenous leukemia, bcr-abl1 positive and 12 more |
| GATA2 | 16 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Chronic eosinophilic leukemia, not otherwise specified, Clonal hematopoiesis and 12 more |
| KRAS | 16 / 30 | Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Cd4+/cd56+ hematodermic neoplasm, Essential thrombocythemia and 12 more |
| SF3B1 | 16 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm, Chronic eosinophilic leukemia, not otherwise specified and 12 more |
| ABL1 | 15 / 30 | Acute leukemia of ambiguous lineage, B-lymphoblastic leukemia/lymphoma, Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm and 11 more |
| IDH1 | 15 / 30 | Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm and 11 more |
| NF1 | 15 / 30 | Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm and 11 more |
| PTPN11 | 15 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Essential thrombocythemia, Myelodysplastic/myeloproliferative neoplasm and 11 more |
| BCR | 14 / 30 | Acute leukemia of ambiguous lineage, B-lymphoblastic leukemia/lymphoma, Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm and 10 more |
| CUX1 | 14 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), Chronic eosinophilic leukemia, not otherwise specified, Essential thrombocythemia, Lymphoid neoplasm and 10 more |
| STAG2 | 14 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Chronic eosinophilic leukemia, not otherwise specified, Lymphoid neoplasm and 10 more |
| BCOR | 13 / 30 | Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Central nervous system anaplastic large cell lymphoma and 9 more |
| MPL | 13 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), Chronic eosinophilic leukemia, not otherwise specified, Essential thrombocythemia, Myelodysplastic/myeloproliferative neoplasm and 9 more |
| SETBP1 | 13 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Chronic eosinophilic leukemia, not otherwise specified, Essential thrombocythemia and 9 more |
| SH2B3 | 13 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), Cd4+/cd56+ hematodermic neoplasm, Chronic eosinophilic leukemia, not otherwise specified, Essential thrombocythemia and 9 more |
| CALR | 12 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), Cd4+/cd56+ hematodermic neoplasm, Essential thrombocythemia, Myelodysplastic/myeloproliferative neoplasm and 8 more |
| NOTCH1 | 12 / 30 | Acute leukemia of ambiguous lineage, Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm, Central nervous system anaplastic large cell lymphoma and 8 more |
| PHF6 | 12 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Essential thrombocythemia, Myelodysplastic/myeloproliferative neoplasm and 8 more |
| WT1 | 12 / 30 | Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Chronic eosinophilic leukemia, not otherwise specified and 8 more |
| ATM | 11 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm, Chronic eosinophilic leukemia, not otherwise specified and 7 more |
| CEBPA | 11 / 30 | Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Chronic eosinophilic leukemia, not otherwise specified, Lymphoid neoplasm and 7 more |
| CSF3R | 11 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), Chronic eosinophilic leukemia, not otherwise specified, Essential thrombocythemia, Myelodysplastic/myeloproliferative neoplasm and 7 more |
| IKZF1 | 11 / 30 | Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), B-lymphoblastic leukemia/lymphoma, Blast phase chronic myelogenous leukemia, bcr-abl1 positive and 7 more |
| JAK3 | 11 / 30 | Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Chronic eosinophilic leukemia, not otherwise specified and 7 more |
| ZRSR2 | 11 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), Cd4+/cd56+ hematodermic neoplasm, Essential thrombocythemia, Myelodysplastic/myeloproliferative neoplasm and 7 more |
| BCORL1 | 10 / 30 | Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Lymphoid neoplasm and 6 more |
| KMT2A | 10 / 30 | Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), B-lymphoblastic leukemia/lymphoma, Blast phase chronic myelogenous leukemia, bcr-abl1 positive and 6 more |
| PTEN | 10 / 30 | Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Chronic eosinophilic leukemia, not otherwise specified, Lymphoid neoplasm and 6 more |
| BRAF | 9 / 30 | Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Cd4+/cd56+ hematodermic neoplasm, Lymphoid neoplasm and 5 more |
| EP300 | 9 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Essential thrombocythemia, Lymphoid neoplasm and 5 more |
| GNAS | 9 / 30 | Essential thrombocythemia, Myelodysplastic/myeloproliferative neoplasm, Myelofibrosis, Myeloid neoplasm and 5 more |
| RAD21 | 9 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm, Lymphoid neoplasm and 5 more |
| RB1 | 9 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), Cd4+/cd56+ hematodermic neoplasm, Chronic eosinophilic leukemia, not otherwise specified, Essential thrombocythemia and 5 more |
| ALK | 8 / 30 | Central nervous system anaplastic large cell lymphoma, Lymphoid neoplasm, Myelofibrosis, Myelomonocytic leukemia and 4 more |
| CDKN2A | 8 / 30 | Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), B-lymphoblastic leukemia/lymphoma, Blast phase chronic myelogenous leukemia, bcr-abl1 positive and 4 more |
| CSF1R | 8 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), Chronic eosinophilic leukemia, not otherwise specified, Essential thrombocythemia, Myelofibrosis and 4 more |
| KMT2C | 8 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Essential thrombocythemia, Lymphoid neoplasm and 4 more |
| KMT2D | 8 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), Lymphoid neoplasm, Myelodysplastic/myeloproliferative neoplasm, Myelofibrosis and 4 more |
| PDGFRB | 8 / 30 | Myelodysplastic/myeloproliferative neoplasm, Myelogenous leukemia, Myelomonocytic leukemia, Myeloproliferative disease, unclassifiable and 4 more |
| PPM1D | 8 / 30 | Essential thrombocythemia, Lymphoid neoplasm, Myelofibrosis, Myeloid neoplasm and 4 more |
| ARID1A | 7 / 30 | Lymphoid neoplasm, Myelodysplastic/myeloproliferative neoplasm, Myelofibrosis, Myeloid neoplasm and 3 more |
| ETNK1 | 7 / 30 | Cd4+/cd56+ hematodermic neoplasm, Chronic eosinophilic leukemia, not otherwise specified, Myelodysplastic/myeloproliferative neoplasm, Myeloid neoplasm and 3 more |
| GATA1 | 7 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Chronic eosinophilic leukemia, not otherwise specified, Myelodysplastic/myeloproliferative neoplasm and 3 more |
| BCL6 | 6 / 30 | Myelodysplastic/myeloproliferative neoplasm, Myeloid neoplasm, Myelomonocytic leukemia, Myeloproliferative disease, unclassifiable and 2 more |
| CBLB | 6 / 30 | Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm, Myeloid neoplasm, Myelomonocytic leukemia and 2 more |
| CREBBP | 6 / 30 | Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Myelodysplastic/myeloproliferative neoplasm, Myeloid neoplasm, Myelomonocytic leukemia and 2 more |
| FAT4 | 6 / 30 | Chronic eosinophilic leukemia, not otherwise specified, Essential thrombocythemia, Myelofibrosis, Myelomonocytic leukemia and 2 more |
| KDM6A | 6 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), Cd4+/cd56+ hematodermic neoplasm, Myelomonocytic leukemia, Myeloproliferative disease, unclassifiable and 2 more |
| STAT5B | 6 / 30 | Chronic eosinophilic leukemia, not otherwise specified, Myelodysplastic/myeloproliferative neoplasm, Myelomonocytic leukemia, Myeloproliferative disease, unclassifiable and 2 more |
| ATRX | 5 / 30 | Cd4+/cd56+ hematodermic neoplasm, Chronic eosinophilic leukemia, not otherwise specified, Myelodysplastic/myeloproliferative neoplasm, Myelofibrosis and 1 more |
| CHEK2 | 5 / 30 | Clonal hematopoiesis, Essential thrombocythemia, Myelofibrosis, Myeloproliferative disorder and 1 more |
| FBXO11 | 5 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Lymphoid neoplasm, Myeloid neoplasm and 1 more |
| FBXW7 | 5 / 30 | Chronic eosinophilic leukemia, not otherwise specified, Lymphoid neoplasm, Myelodysplastic/myeloproliferative neoplasm, Myeloid neoplasm and 1 more |
| GATA3 | 5 / 30 | B-lymphoblastic leukemia/lymphoma, Myeloid neoplasm, Myeloproliferative disease, unclassifiable, Neutrophilic leukemia and 1 more |
| PCM1 | 5 / 30 | Acute leukemia of ambiguous lineage, Chronic eosinophilic leukemia, not otherwise specified, Myelodysplastic/myeloproliferative neoplasm, Neutrophilic leukemia and 1 more |
| PDGFRA | 5 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), B-lymphoblastic leukemia/lymphoma, Chronic eosinophilic leukemia, not otherwise specified, Myelodysplastic/myeloproliferative neoplasm and 1 more |
| PTCH1 | 5 / 30 | Lymphoid neoplasm, Myelofibrosis, Myelomonocytic leukemia, Testicular leydig cell tumor and 1 more |
| TCF3 | 5 / 30 | Acute leukemia of ambiguous lineage, B-lymphoblastic leukemia/lymphoma, Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Myeloid neoplasm and 1 more |
| CARD11 | 4 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), Lymphoid neoplasm, Myeloid neoplasm, Neutrophilic leukemia |
| EWSR1 | 4 / 30 | Acute leukemia of ambiguous lineage, Lymphoid neoplasm, Myelofibrosis, Therapy related acute myeloid leukemia and myelodysplastic syndrome |
| HRAS | 4 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), Cd4+/cd56+ hematodermic neoplasm, Lymphoid neoplasm, Myelomonocytic leukemia |
| JAK1 | 4 / 30 | Acute leukemia of ambiguous lineage, Acute myeloid leukemia, t(3;5)(q25;q34), Myelomonocytic leukemia, Myeloproliferative disease, unclassifiable |
| MET | 4 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), Cd4+/cd56+ hematodermic neoplasm, Myelomonocytic leukemia, Polycythemia vera |
| MUC16 | 4 / 30 | Essential thrombocythemia, Myelofibrosis, Polycythemia vera, Therapy-related myeloid neoplasm |
| NTRK2 | 4 / 30 | Myelofibrosis, Myeloid neoplasm, Neutrophilic leukemia, Polycythemia vera |
| NUP214 | 4 / 30 | Acute leukemia of ambiguous lineage, Myelomonocytic leukemia, Myeloproliferative disorder, T-lymphoblastic lymphoma |
| PRDM1 | 4 / 30 | Essential thrombocythemia, Myeloid neoplasm, Neutrophilic leukemia, Polycythemia vera |
| SMC1A | 4 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), Myelomonocytic leukemia, Myeloproliferative disease, unclassifiable, Neutrophilic leukemia |
| SUZ12 | 4 / 30 | Myelofibrosis, Myelomonocytic leukemia, Polycythemia vera, Therapy related acute myeloid leukemia and myelodysplastic syndrome |
| APC | 3 / 30 | Cd4+/cd56+ hematodermic neoplasm, Myelofibrosis, Polycythemia vera |
| ASXL2 | 3 / 30 | Myelodysplastic/myeloproliferative neoplasm, Myeloid neoplasm, Neutrophilic leukemia |
| CBFA2T3 | 3 / 30 | Essential thrombocythemia, Myelomonocytic leukemia, Myeloproliferative disorder |
| CCND3 | 3 / 30 | Acute leukemia of ambiguous lineage, Myeloid neoplasm, Systemic mastocytosis |
| CDKN1B | 3 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), Myelodysplastic/myeloproliferative neoplasm, Myelomonocytic leukemia |
| CHD4 | 3 / 30 | Essential thrombocythemia, Polycythemia vera, Thrombocytosis |
| CTCF | 3 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), Myelomonocytic leukemia, Myeloproliferative disorder |
| DICER1 | 3 / 30 | Essential thrombocythemia, Lymphoid neoplasm, Myelofibrosis |
| EML4 | 3 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), Lymphoid neoplasm, Polycythemia vera |
| EPHA7 | 3 / 30 | Essential thrombocythemia, Mast cell neoplasm, Myelofibrosis |
| ERBB4 | 3 / 30 | Essential thrombocythemia, Myelomonocytic leukemia, Systemic mastocytosis |
| FAT1 | 3 / 30 | Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Myelofibrosis, Polycythemia vera |
| HLA-A | 3 / 30 | Myelodysplastic/myeloproliferative neoplasm, Myeloid neoplasm, Neutrophilic leukemia |
| IKZF3 | 3 / 30 | Blast phase chronic myelogenous leukemia, bcr-abl1 positive, Cd4+/cd56+ hematodermic neoplasm, Lymphoid neoplasm |
| MALT1 | 3 / 30 | Myeloid neoplasm, Myeloproliferative disease, unclassifiable, Neutrophilic leukemia |
| MED12 | 3 / 30 | Acute myeloid leukemia, t(3;5)(q25;q34), Chronic eosinophilic leukemia, not otherwise specified, Myeloproliferative disease, unclassifiable |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Pathways in cancer | KEGG | 106 / 533 | 4.9× | 1.65e-45 | 1.76e-41 ✓ sig. |
| Transcriptional misregulation in cancer | KEGG | 48 / 198 | 6.0× | 1.56e-24 | 2.32e-21 ✓ sig. |
| Prostate cancer | KEGG | 34 / 98 | 8.6× | 3.23e-23 | 4.13e-20 ✓ sig. |
| EGFR tyrosine kinase inhibitor resistance | KEGG | 31 / 80 | 9.6× | 5.88e-23 | 7.37e-20 ✓ sig. |
| Acute myeloid leukemia | KEGG | 27 / 68 | 9.8× | 1.77e-20 | 1.42e-17 ✓ sig. |
| Chronic myeloid leukemia | KEGG | 28 / 77 | 9.0× | 5.76e-20 | 4.26e-17 ✓ sig. |
| Central carbon metabolism in cancer | KEGG | 27 / 71 | 9.4× | 6.81e-20 | 5.01e-17 ✓ sig. |
| Endometrial cancer | KEGG | 25 / 59 | 10.5× | 6.92e-20 | 5.06e-17 ✓ sig. |
| PI3K-Akt signaling pathway | KEGG | 57 / 361 | 3.9× | 3.36e-19 | 2.21e-16 ✓ sig. |
| Melanoma | KEGG | 26 / 73 | 8.8× | 2.31e-18 | 1.31e-15 ✓ sig. |
| Proteoglycans in cancer | KEGG | 41 / 204 | 5.0× | 6.81e-18 | 3.57e-15 ✓ sig. |
| Colorectal cancer | KEGG | 27 / 87 | 7.7× | 2.95e-17 | 1.39e-14 ✓ sig. |
| Non-small cell lung cancer | KEGG | 25 / 73 | 8.5× | 3.13e-17 | 1.46e-14 ✓ sig. |
| JAK-STAT signaling pathway | KEGG | 36 / 168 | 5.3× | 8.74e-17 | 3.68e-14 ✓ sig. |
| MicroRNAs in cancer | KEGG | 48 / 311 | 3.8× | 6.72e-16 | 2.41e-13 ✓ sig. |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| positive regulation of transcription by RNA polymerase II | GO:0045944 | 119 / 1,208 | 3.8× | 2.97e-38 | 3.23e-34 ✓ sig. |
| positive regulation of DNA-templated transcription | GO:0045893 | 85 / 778 | 4.2× | 3.89e-30 | 2.35e-26 ✓ sig. |
| negative regulation of transcription by RNA polymerase II | GO:0000122 | 89 / 1,002 | 3.4× | 5.63e-25 | 1.74e-21 ✓ sig. |
| positive regulation of gene expression | GO:0010628 | 59 / 504 | 4.5× | 1.78e-22 | 4.01e-19 ✓ sig. |
| positive regulation of cell population proliferation | GO:0008284 | 58 / 532 | 4.2× | 1.42e-20 | 2.46e-17 ✓ sig. |
| cell population proliferation | GO:0008283 | 41 / 263 | 6.0× | 1.84e-20 | 3.13e-17 ✓ sig. |
| negative regulation of DNA-templated transcription | GO:0045892 | 63 / 631 | 3.8× | 2.70e-20 | 4.53e-17 ✓ sig. |
| regulation of cell population proliferation | GO:0042127 | 35 / 201 | 6.7× | 3.23e-19 | 4.61e-16 ✓ sig. |
| regulation of gene expression | GO:0010468 | 47 / 402 | 4.5× | 4.82e-18 | 5.79e-15 ✓ sig. |
| apoptotic process | GO:0006915 | 63 / 747 | 3.2× | 1.26e-16 | 1.21e-13 ✓ sig. |
| chromatin remodeling | GO:0006338 | 40 / 320 | 4.8× | 1.62e-16 | 1.52e-13 ✓ sig. |
| regulation of transcription by RNA polymerase II | GO:0006357 | 98 / 1,602 | 2.4× | 6.42e-16 | 5.42e-13 ✓ sig. |
| positive regulation of miRNA transcription | GO:1902895 | 18 / 56 | 12.4× | 1.85e-15 | 1.46e-12 ✓ sig. |
| DNA damage response | GO:0006974 | 52 / 577 | 3.5× | 5.03e-15 | 3.64e-12 ✓ sig. |
| regulation of DNA-templated transcription | GO:0006355 | 90 / 1,454 | 2.4× | 6.42e-15 | 4.55e-12 ✓ sig. |